carvedilol has been researched along with Atherogenesis in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "It has been shown that oxidative stress may play an important role in the development of atherosclerosis, and carvedilol has the capacity of reducing oxidative stress." | 7.78 | Carvedilol reduces the severity of atherosclerosis in apolipoprotein E-deficient mice via reducing superoxide production. ( Fujita, M; Hirano, E; Kimura, T; Kishimoto, C; Shimada, K, 2012) |
| "40 rats were randomly divided into 4 groups: control, untreated atherosclerosis group, atherosclerotic rats treated with carvedilol (10mg/kg/d) and atherosclerotic rats treated with alendronate sodium (10mg/kg/d)." | 4.02 | Matrix metalloproteinase 9 a potential major player connecting atherosclerosis and osteoporosis in high fat diet fed rats. ( Abdelgwad, M; Estaphan, S; Kamar, S; Mostafa, S; Rashed, L; Sabry, M, 2021) |
| "It has been shown that oxidative stress may play an important role in the development of atherosclerosis, and carvedilol has the capacity of reducing oxidative stress." | 3.78 | Carvedilol reduces the severity of atherosclerosis in apolipoprotein E-deficient mice via reducing superoxide production. ( Fujita, M; Hirano, E; Kimura, T; Kishimoto, C; Shimada, K, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SJ | 1 |
| Tsui, PF | 1 |
| Chuang, YP | 1 |
| Chiang, DM | 1 |
| Chen, LW | 1 |
| Liu, ST | 1 |
| Lin, FY | 2 |
| Huang, SM | 1 |
| Lin, SH | 1 |
| Wu, WL | 1 |
| Tsai, MC | 1 |
| Lin, CS | 1 |
| Sabry, M | 1 |
| Mostafa, S | 1 |
| Rashed, L | 1 |
| Abdelgwad, M | 1 |
| Kamar, S | 1 |
| Estaphan, S | 1 |
| Textor, SC | 1 |
| Besler, C | 1 |
| Doerries, C | 1 |
| Giannotti, G | 1 |
| Lüscher, TF | 1 |
| Landmesser, U | 1 |
| Shimada, K | 1 |
| Hirano, E | 1 |
| Kimura, T | 1 |
| Fujita, M | 1 |
| Kishimoto, C | 1 |
| Wu, TC | 1 |
| Chen, YH | 1 |
| Leu, HB | 1 |
| Chen, YL | 1 |
| Lin, SJ | 1 |
| Chen, JW | 1 |
| de Nigris, F | 1 |
| Mancini, FP | 1 |
| Balestrieri, ML | 1 |
| Byrns, R | 1 |
| Fiorito, C | 1 |
| Williams-Ignarro, S | 1 |
| Palagiano, A | 1 |
| Crimi, E | 1 |
| Ignarro, LJ | 1 |
| Napoli, C | 1 |
1 review available for carvedilol and Atherogenesis
| Article | Year |
|---|---|
Pharmacological approaches to improve endothelial repair mechanisms.
Topics: AC133 Antigen; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2008 |
6 other studies available for carvedilol and Atherogenesis
| Article | Year |
|---|---|
Carvedilol Ameliorates Experimental Atherosclerosis by Regulating Cholesterol Efflux and Exosome Functions.
Topics: Animals; Antihypertensive Agents; Atherosclerosis; ATP Binding Cassette Transporter 1; Biological Tr | 2019 |
Matrix metalloproteinase 9 a potential major player connecting atherosclerosis and osteoporosis in high fat diet fed rats.
Topics: Alendronate; Alkaline Phosphatase; Animals; Atherosclerosis; Biomarkers; Bone Density; Bone Remodeli | 2021 |
Attending rounds: a patient with accelerated hypertension and an atrophic kidney.
Topics: Aged; Amides; Antihypertensive Agents; Atherosclerosis; Atrophy; Blood Pressure; Carbazoles; Carvedi | 2014 |
Carvedilol reduces the severity of atherosclerosis in apolipoprotein E-deficient mice via reducing superoxide production.
Topics: Adrenergic beta-Antagonists; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Blood Pressure; Car | 2012 |
Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Aorta, Abdominal; Atherosclerosis; Carbazoles; C | 2007 |
Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits.
Topics: Adrenergic beta-Antagonists; Animal Feed; Animals; Antihypertensive Agents; Aorta; Atherosclerosis; | 2008 |